We conclude that the effects of standard dose flutamide on plasma insulin and glucose occur in a differential and age‐dependent manner during the first 3 weeks of neonatal life, which renders standard doses of flutamide a less than the optimal agent for studying the effects of androgen on neonatal pancreatic endocrine function and common neonatal pathologies such as maternal hyperandrogenism, glucose intolerance, and insulin resistance. The gene discussed is INS; the disease is Glucose intolerance.